Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) saw a significant decrease in short interest in March. As of March 31st, there was short interest totalling 5,280,000 shares, a decrease of 5.9% from the March 15th total of 5,610,000 shares. Based on an average daily volume of 1,200,000 shares, the short-interest ratio is currently 4.4 days.
Alpine Immune Sciences Stock Down 0.1 %
Shares of NASDAQ:ALPN opened at $64.46 on Thursday. Alpine Immune Sciences has a 52 week low of $6.71 and a 52 week high of $64.57. The company has a 50 day moving average price of $38.66 and a two-hundred day moving average price of $24.15.
Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) last issued its earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The firm had revenue of $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. As a group, equities research analysts anticipate that Alpine Immune Sciences will post -1.74 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Analysis on Alpine Immune Sciences
Institutional Investors Weigh In On Alpine Immune Sciences
Several large investors have recently bought and sold shares of ALPN. JPMorgan Chase & Co. increased its stake in Alpine Immune Sciences by 23.4% in the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,697 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Alpine Immune Sciences by 1.4% during the first quarter. Vanguard Group Inc. now owns 707,598 shares of the biotechnology company’s stock worth $6,347,000 after acquiring an additional 9,844 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Alpine Immune Sciences by 7.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 32,417 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 2,294 shares in the last quarter. State Street Corp increased its position in shares of Alpine Immune Sciences by 7.1% during the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company’s stock worth $1,979,000 after acquiring an additional 14,609 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Alpine Immune Sciences by 70.8% during the first quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 9,471 shares in the last quarter. Institutional investors own 75.17% of the company’s stock.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
Read More
- Five stocks we like better than Alpine Immune Sciences
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- United Airlines Soars on Earnings Beat
- How to Calculate Retirement Income: MarketBeat’s Calculator
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What are earnings reports?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.